These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19429509)

  • 21. [Biosimilar: can we manage biopharmaceutical heterogeneity?].
    Ranieri E
    G Ital Nefrol; 2008; 25(3):275. PubMed ID: 18473296
    [No Abstract]   [Full Text] [Related]  

  • 22. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The problematic of original and generic drugs and biosimilars--switching of drugs today and tomorrow with the main targeting on biotechnologies-associated risks].
    Svoboda T
    Klin Onkol; 2010; 23(6):416-20. PubMed ID: 21351418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know.
    Strober BE; Armour K; Romiti R; Smith C; Tebbey PW; Menter A; Leonardi C
    J Am Acad Dermatol; 2012 Feb; 66(2):317-22. PubMed ID: 22243723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.
    Blackstone EA; Fuhr JP
    Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statistical assessment of biosimilar products.
    Chow SC; Liu JP
    J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of biosimilars--pharmacokinetic and pharmacodynamic considerations.
    Wang YM; Chow AT
    J Biopharm Stat; 2010 Jan; 20(1):46-61. PubMed ID: 20077248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bills target biosimilar drugs.
    Wadman M
    Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
    [No Abstract]   [Full Text] [Related]  

  • 32. The protein science of biosimilars.
    Kuhlmann M; Covic A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v4-8. PubMed ID: 16959791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Biosimilar products comparable to original preparations. The Medical Products Agency will not yet classify the agents as generics].
    Welin M; Liliemark J
    Lakartidningen; 2009 Jun 3-9; 106(23):1547-8. PubMed ID: 19583011
    [No Abstract]   [Full Text] [Related]  

  • 34. Biosimilars in clinical practice.
    Mikhail A
    Kidney Blood Press Res; 2007; 30 Suppl 1():18-22. PubMed ID: 17726339
    [No Abstract]   [Full Text] [Related]  

  • 35. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
    Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biosimilars approval process.
    Zuñiga L; Calvo B
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concept of biosimilar products in Jordan.
    Haddadin RD
    Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative testing and pharmacovigilance of biosimilars.
    Locatelli F; Roger S
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biosimilar therapeutic agents: issues with bioequivalence and immunogenicity.
    Schellekens H
    Eur J Clin Invest; 2004 Dec; 34(12):797-9. PubMed ID: 15606720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.